Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Elvira Valera"'
Autor:
Elvira Valera, Brian Spencer, Jennifer Mott, Margarita Trejo, Anthony Adame, Michael Mante, Edward Rockenstein, Juan C. Troncoso, Thomas G. Beach, Eliezer Masliah, Paula Desplats
Publikováno v:
Frontiers in Molecular Neuroscience, Vol 10 (2017)
Synucleinopathies, neurodegenerative disorders with alpha-synuclein (α-syn) accumulation, are the second leading cause of neurodegeneration in the elderly, however no effective disease-modifying alternatives exist for these diseases. Multiple system
Externí odkaz:
https://doaj.org/article/910109e466e14f79a9629629f4f5e2a1
Autor:
Elvira Valera, Michael J Isaacs, Yasuhiko Kawakami, Juan Carlos Izpisúa Belmonte, Senyon Choe
Publikováno v:
PLoS ONE, Vol 5, Iss 6, p e11167 (2010)
Bone Morphogenetic Protein (BMP) signaling pathways are involved in differentiation of stem cells into diverse cell types, and thus BMPs can be used as main guidance molecules for in vitro differentiation of human stem cells.We have analyzed the abil
Externí odkaz:
https://doaj.org/article/de42eca139cc4688ba30638a8afe3088
Publikováno v:
Mol Neurobiol
Multiple systems atrophy (MSA) is a rare neurodegenerative disorder characterized by the accumulation of α-synuclein in glial cells and neurodegeneration in the striatum, substantia nigra, and cerebellum. Aberrant miRNA regulation has been associate
Autor:
Paula Desplats, Eliezer Masliah, María J. Marquine, Jerel Adam Fields, Benchawanna Soontornniyomkij, Arina Alexeeva, Brian Spencer, Cristian L. Achim, Sarah Gough, Elvira Valera, Emma Martine Qvale, Mary K Swinton
Publikováno v:
Journal of neurochemistry, vol 147, iss 6
Neuroinflammation is a common pathological correlate of HIV-associated neurocognitive disorders (HAND) in individuals on antiretroviral therapy (ART). Triggering receptor expressed on myeloid cells 2 (TREM2) regulates neuroinflammation, clears extrac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a88c7b5a0e264b0889532924b6e658d1
https://escholarship.org/uc/item/7tk7w53g
https://escholarship.org/uc/item/7tk7w53g
Autor:
Eliezer Masliah, Elvira Valera
Publikováno v:
Journal of Neurochemistry. 139:346-352
The lack of effective therapies for neurodegenerative disorders is one of the most relevant challenges of this century, considering that, as the global population ages, the incidence of these type of diseases is quickly on the rise. Among these disor
Publikováno v:
Neuropathology and Applied Neurobiology. 42:95-106
Neurodegenerative disorders with alpha-synuclein (α-syn) accumulation (synucleinopathies) include Parkinson's disease, Parkinson's disease dementia, dementia with Lewy bodies and multiple system atrophy (MSA). Due to the involvement of toxic α-syn
Autor:
Elvira Valera, Eliezer Masliah
Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by the abnormal accumulation of toxic forms of the synaptic protein alpha-synuclein (α-syn) within oligodendrocytes and neurons. The presence of α-syn within oligoden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd23efeaa9bc45e012ae13ccd7e5da15
https://europepmc.org/articles/PMC5954415/
https://europepmc.org/articles/PMC5954415/
Publikováno v:
Neurotherapeutics. 13:179-189
Disease-modifying alternatives are sorely needed for the treatment of neurodegenerative disorders, a group of diseases that afflict approximately 50 million Americans annually. Immunotherapy is one of the most developed approaches in this direction.
Autor:
Eliezer Masliah, Elvira Valera
Publikováno v:
Movement Disorders. 31:225-234
Currently there are no disease-modifying alternatives for the treatment of most neurodegenerative disorders. The available therapies for diseases such as Parkinson's disease (PD), PD dementia (PDD), dementia with Lewy bodies (DLB), and multiple syste
Autor:
Nadia Stefanova, Edward Rockenstein, Eliezer Masliah, Gregor K. Wenning, Elvira Valera, Cassia R. Overk
Publikováno v:
Acta neuropathologica. 135(1)
Multiple system atrophy (MSA) is a rapidly progressing fatal synucleinopathy of the aging population characterized by parkinsonism, dysautonomia, and in some cases ataxia. Unlike other synucleinopathies, in this disorder the synaptic protein, α-synu